Celiac disease now affects about one person in a hundred in Europe and North America. In this review, we consider a number of important and exciting recent developments, such as clinical associations, HLA-DQ2 and HLA-DQ8 predispositions, the concept of potential celiac disease, the use of new imaging/endoscopy techniques, and the development of refractory disease. This review will be of use to all internists, pediatricians and gastroenterologists.
INTRODUCTION
Celiac disease (CD) is an immune-mediated enteropathy c harac terized by intoleranc e to gluten. CD is usually c harac terized by various gastrointestinal (GI) symptoms (e.g. diarrhea, malabsorption, weight loss) assoc iated with c onsumption of grains c ontaining gluten (wheat, barley, rye). Although some CD patients may have primarily GI symptoms, CD may be detec ted due to assoc iated extraintestinal disorders, even without GI symptoms, or due to sc reening for CD based on a positive family history. CD has a strong assoc iation with HLA-DQ2 and HLA-DQ8. Serological testing for antibodies to tissue transglutaminase (tTG) is usually positive (-95%) in the untreated patient. Endosc opic and histologic al damage seen in the proximal intestine is c harac teristic , but not diagnostic . As CD is defined to be a gluten-sensitive enteropathy, definitive diagnosis ultimately depends on a positive small bowel biopsy and demonstration of a response to a gluten-free diet (GFD) [1] . Common serologic al c hanges inc lude the appearanc e of anti-tTG and other antibodies, e.g. endomysial antibodies (EMA). These antibodies have been reported in some, but not all studies, to dec line or disappear in assoc iation with a c linic al and/or histologic al response to a gluten-free diet.
The c linic al spec trum of CD inc ludes patients with classical gastrointestinal symptoms (e.g. diarrhea and weight loss), those who are detec ted on sc reening bec ause of a family history of CD or having a CD-assoc iated autoimmune c ondition, or those who have a predisposition for developing CD but at a partic ular time of testing, c onc eivably c ould have no symptoms, negative CD serology and a histologic ally normal small bowel biopsy. Now, a CD-specific quality of life instrument has also been developed and validated psyc hometric ally [2] , and may prove useful in everyday c linic al prac tic e.
EPIDEMIOLOGY
CD is highly prevalent in Cauc asian populations and their desc endants. The age of c linic al onset (based on diagnosis) is often desc ribed by some experts as bimodal: the first peak is at 8 to 12 mo of age, and the second during the third to fourth dec ades of life [3] . Rec ent studies suggest, however, that CD should be c onsidered as a disorder that has a risk of developing throughout life, even in the elderly. Overall, CD is twice as frequent among females as c ompared to males, possibly bec ause the nec essary HLA haplotypes, DQ2/DQ8, are more frequent in female than in male CD patients (i.e. 94% vs 85%) [4] . In addition, CD may be detected more frequently in females because females tend to seek medical care more often than males, usually at a younger age. With aging, however, this female predominant pattern disappears. In the elderly, the ratio of newly diagnosed males is equivalent to newly diagnosed females. In the few DQ2/DQ8 -negative CD patients, there is a male exc ess, and only inheritanc e of a paternal DQ2 haplotype leads to a daughter's predominanc e [4] . While it is estimated that CD affec ts up to 2% of Caucasians, the risk is higher in first-degree relatives of affec ted sibling pairs (17%), monozygotic twins (75%), and HLA-identic al siblings (40%). Indeed, the single most important risk factor for celiac disease is having a first-degree relative with already-defined CD, partic ularly a sibling [5] . The estimated prevalence of CD in first-degree relatives living in Minneapolis, USA is 11% of all affec ted family members who carried at-risk genotypes (HLA-DQ2 in more than 90% of c ases, and the remainder c arrying HLA-DQ8). About half of these persons have c linic ally "silent disease", and yet, their small bowel biopsies may show severe arc hitec tural c hanges [6] . This apparent disc onnec tion in some patients between severity of symptoms with CD and the severity of histologic al abnormalities (typic ally defined in the proximal small bowel) may reflect the variable extent of histologic al involvement further along the length of the small intestine.
The prevalenc e of CD appears to be inc reasing, partic ularly as the population ages [7] . CD in the elderly has been reviewed and also likely reflects increased recognition of undiagnosed CD in this age group [8] [9] [10] . The estimated prevalenc e of CD in individuals in the United Kingdom between 45 to 76 years of age is approximately 1.2%. About 20% of all newly diagnosed c eliac c ases are over 60 years of age. The c linic al presentation in these older individuals is variable, ranging from "silent" disease, to vague abdominal c omplaints, to anemia. These limited symptoms c ould also lead to a delay in diagnosis.
Prolonged gluten exposure in undiagnosed CD is seen to inc rease the inc idenc e of autoimmune diseases, suc h as diabetes and autoimmune thyroiditis. As far as gastrointestinal c omplic ations are c onc erned, it is important to rule out c ollagenous and lymphoc ytic c olitis [11, 12] , whic h may be mistaken for non-compliance with a gluten-free diet (GFD). Eight perc ent of elderly persons in nursing homes or long-term c are c enters may have assoc iated small bowel bac terial overgrowth, manifesting with malabsorption and diarrhea-like symptoms. Nutrient depletion in these individuals is c ommon, and the inc idenc e of osteopenic bone disease is inc reased. Finally, neurologic al disorders, suc h as dementia, are bec oming inc reasingly rec ognized in elderly patients with CD [13] . Sc reening serologic al tests (IgA and IgG) appear to be age-independent in adults. However, the elderly seem to have an inc reased inc idenc e of sero-negative CD. Interestingly, the fate of different c eliac antibodies in genetic ally at-risk children on a normal diet has been assessed, and, remarkably, these appear to spontaneously disappear [14] . Specifically, antibodies to tTG and EMA were spontaneously lost in 49% and 45%, despite c ontinuing gluten exposure. Although the procedural risk of endoscopy and biopsy may be marginally inc reased in the elderly, endosc opic biopsy remains c ruc ial as the "gold standard" for diagnosis of CD in this age group as well as in all other age groups.
GENETICS
It is c onc eivable that CD c ould be a heterogeneous disorder, not only with differing c linic al presentations, but also different degrees of pathologic al c hange in the small intestinal muc osa. Further morphometric and immunohistoc hemic al studies from geographic ally and genetically diverse populations are needed to confirm observations on inc reased intraepithelial lymphoc ytes (IELs) in otherwise arc hitec turally normal small intestine.
A small percentage of EMA-positive patients may have a small bowel biopsy in whic h the muc osa might be c onsidered by some pathologists to be arc hitec turally normal. From 409 c hildren who were positive for c eliac -related antibodies, 24 (5.9%) of the individuals were reported to have an arc hitec turally normal small intestinal muc osa, 46% (11 of these 24 patients) had inc reased CD3+ intraepithelial lymphoc ytes, and 71% (17 of the 24) had an inc reased density of gamma-delta + c ells [15] . In 17 of these 24 persons (70%), the number of lamina propria CD25+ c ells was inc reased, and/or the expression of ICAM-1 and c rypt HLA-DR was enhanc ed. Interestingly, in those persons with apparently normal jejunal histology, there appeared to be immunohistologic al evidenc e of immune ac tivation in the epithelium, lamina propria and intestinal c rypts. A GFD is usually not rec ommended in individuals with an arc hitec turally-normal small bowel biopsy. Sophisticated immunohistochemical findings, such as these, raise the question as to whether definition of "normal" needs to be extended, and whether suc h subjec ts with abnormal antibodies in the intestinal biopsy may need further monitoring to determine if a GFD is indic ated. In addition, duodenal muc osal tTG detec tion improves the sensitivity of diagnosis in CD for those with very mild histologic al c hanges, i.e. Marsh 1 lesions [16] . Thus, the definition of CD may c onc eivably extend to persons with an arc hitec turally normal muc osal biopsy, but with abnormal CD-assoc iated immunohistoc hemic al c hanges. Additional studies are needed to confirm, evaluate and further elucidate these interesting observations. Gluten has specific peptide sequences which show HLA-DQ2 or HLA-DQ8 restric tive binding motifs ac ross the various gluten proteins. About 40% of the heritability of CD includes the human leukocyte antigen HLA-DQ2 and HLA-DQ8 heterodimers. The HLA DQ2 and HLA-DQ8 molec ules are nec essary to develop CD, but are not, in themselves, sufficient for phenotypic expression of the disease. Indeed, HLA markers only explain an estimated 40% of the heritable risk for CD. Therefore, other non-HLA genes must also be involved. One of these may relate to genetic variants on c hromosome 19, in the myosin IXB gene (i.e. MYO9B), and may potentially predic t responsiveness to a GFD [17] . CD-assoc iated HLA-DQ molec ules bind and present gluten peptides to antigen-specific T-cells in the intestinal muc osa, and induc e T-c ell proliferation as well as c ytokine secretion. Siblings who share HLA haplotypes have a greater likelihood of concordance with CD than the generally estimated risk for siblings. A small percentage of CD patients are DQ-2 negative, usually being DR4-positive for the c lass 2 antigen, DQ8. Carrying two c opies of DQB1*02 is associated with an even greater risk for CD, but does not predic t an earlier age of onset of disease or disease severity. This suggests that assessment of c opy number of the DQB1*02 allele could permit stratification of risk [18] . In twin studies in whic h CD was diagnosed by small bowel biopsy and serology in one twin, monozygotic twin pairs had a high probability of being c onc ordant with CD in the sec ond twin: monozygotic and dizygotic c otwins had 70% and 9% c umulative probability of having symptomatic or "silent" forms of CD, respec tively, within 5 years [19] . Under ACE (additive genetic , c ommon and unshared environmental fac tors/models) with CD prevalenc es of 1/91 and 1/1000, heritability estimates were 87% and 57%, respec tively [19] . The overall risk of siblings of children with CD developing CD was 10% in an Italian population, but the risk estimate ranged from 0.1% to 29% when HLA-DQ information of the proband, parents and sibling was c onsidered [20] . The risk for the sibling developing CD was less than 1% for 40% of the sibs of the probands, 1% to 10% for 30% of the probands, and above 25% for the remaining 30% of the siblings. Thus, information about the risk for a second child to develop CD can be provided to parents with a c hild with CD. This antenatal estimate of the risk of CD in the child may be useful to provide early diagnosis and management, as well as providing foc used and specific follow-up depending upon the risk stratification. Of importanc e, bec ause CD is treated with a GFD and the resultant quality of life of the CD patient is high, the antenatal diagnosis of CD should not be used as a reason to c onsider termination of the pregnanc y.
A double dose of DR3 (often with DQ2) is assoc iated with an even higher risk of development of CD. HLA genotyping is thought to be useful to exc lude CD in family members, or in persons in whom there is an increased risk of CD, suc h as those with Turner syndrome or Down's syndrome [21] . A strategy that combines gene expression profiling of intestinal biopsy specimens, linkage region information, and different bio-informatic tools for the selec tion of potential regulatory single-nuc leotide polymorphisms (SNPs) has been used to searc h for novel c andidate determinants of predisposition to CD in previously identified linkage regions [22] . Abnormalities in func tional proteins have been observed in CD. By using genetic assoc iation analysis with a SNPs approac h, the tight junc tion permeability barrier genes, KRD 3 (2SNPs) and MAGI 2 (2SNPs), were shown to be assoc iated with CD in British and Dutc h persons [23] . In addition to the involvement of HLA classⅠ restric ted CD8+ T-c ells, the innate immune system may also be involved in CD. In the muc osa of untreated CD, there is an inc rease in ac tivated CD8+ T-c ells c ontaining large granzyme-B (GrB)-positive granules, as well as c ell surfac e expression of the Fas ligand (FasL). CD8+ T-c ell c ytotoxic ity oc c urs in the muc osa of patients with ac tive CD (through Fas and FasL-mediated killing of enterocytes). The gliadin interac tion for this CD8+ T c ell-mediated response (oc c urring through TCR/HLA c lass Ⅰ) induc es enteroc yte apoptosis [24] . Variation among four closely linked genes on chromosome 4q27 represents a non-HLA genetic risk factor for CD, mapping to a region that c ontains IL2, IL21, TENR, and K1AA1109 [25] . Also, multiple c ommon variants for CD influencing immune gene expression have been defined with sec ond generation genome wide assoc iation studies [26] . Genetic studies have also recently identified nine non-HLA loci that contribute to CD risk. Combining HLA and non-HLA risk genotypes increases the sensitivity of CD diagnosis by 6.2% c ompared with using only HLA for identific ation, with only a slight dec rease in spec ific ity [27] .
There may be a quantitative relationship between the type and proportion of DQ heterodimers and the risk of CD [28] .
PATHOGENESIS
Gliadins, derived from an alcohol soluble fraction of gluten, are storage proteins that are ingredients in wheat, barley and rye as well as other grains that c ontain gluten (albeit of less importanc e). Gliadins are c harac terized by a high c ontent of glutamine and proline residues. Glutenins are insoluble in aqueous alcohol and are different in struc ture from the glutens. The early immune response in CD patients is direc ted towards several of these peptides, while the long-standing inflammatory response may be driven by gluten peptides deamidated or c rosslinked by tTG and bound more tightly to HLA-DQ2 and HLA-DQ8. The tTG catalyzed modifications in gliadin are not restric ted to single gliadin types or epitopes [29] . Prolamines in barley and rye are known as hordein and secalin, respectively. These barley and rye prolamines induc e an mRNA interferon-gamma response in c eliac muc osa [30] . The α-2 gliadin-33mer appears to c ross the brush border membrane (BBM) of the jejunal enteroc yte by a dose-dependent mec hanism. Both the unc leaved as well as the degraded form of the 33mer transloc ate into the enteroc yte [31] . Interferon-gamma enhanc es the trans-loc ation of the 33mer.
After passage ac ross the BBM, gliadins trigger a Th-1 type-dependent inflammatory reac tion. The effec ts of gliadin peptides and A-gliadin peptide P31-43 on c ell lines and c ultured small intestinal biopsies are mediated through epidermal growth fac tor rec eptor (EGFR) ac tivation by interfering with EGFR endoc ytosis [32] . Gliadin has an immunogenic effec t, but also direc tly affec ts c ultured c ells and intestinal preparations by way of separate peptides suc h as A-gliadin p31-43 (P31-43). The gliadin-induc ed delay of EGFR endoc ytosis in c ultured intestinal biopsies suggests a role for EGFR ac tivation in CD [32] . A 33 amino ac id fragment of α-2 gliadin is an important trigger of the inflammatory process. In patients with active CD, there is transepithelial translocation of the attack 33mer, as well as inc omplete degradation of the 33mer during intestinal transport.
In persons with active CD, there is a marked accumulation of polarized Th-1 c ells that produc e large amounts of interferon γ (IFNγ). T-bet, a member of the T-box family of transc ription fac tors, is present in CD4+ and CD8+ mucosal T cells in patients with CD. Interleukin 21 (IL-21) is present in ac tivated CD4+ T c ells, as well as in natural killer T cells (NK T cells). IL-21 regulates the production of cytokines by T cell subsets. IL-21 increases the expression of Stat4 and T-bet, and stimulates the produc tion of IFNγ in human T c ells. In duodenal muc osal biopsies from patients with CD, there is enhanc ed IL-21 RNA and protein expression, and neutralization of IL-21 largely prevents peptic -tryptic and digest-enhanc ed IL-21 expression [33, 34] . In persons with a genetic susc eptibility to develop CD, gliadin interac ts with the intestine to trigger disassembly of the inter-enteroc yte tight junc tions (TJs). The 2α-gliadin 20mer synthetic peptides of gliadin bind to the chemokine rec eptor, CXCR3. This binding induc es MyD88-dependent zonulin release. In turn, zonulin release leads to inc reased intestinal permeability [35] . Inc reased intestinal permeability oc c urs prior to the onset of c linic ally apparent CD. Even on a GFD, the initially enhanc ed intestinal permeability does not nec essarily return to normal.
Another important aspec t related to the pathogenesis of CD may inc lude the intestinal mic roflora that may be c entral to the c linic al expression of the disease. In one rec ent report, enric hment in the muc osa-assoc iated mic robiota with rod-shaped bac teria in those that developed CD may have c ontributed to the so-c alled "epidemic " in Swedish c hildren less than two years of age [36] . Finally, other rec ent studies related to CD pathogenesis have direc tly used intestinal biopsy spec imens from CD and non-CD persons. For example, IL-15 receptor α mRNA expression is higher in duodenal biopsies from CD c ompared to non-CD persons, regardless of whether the CD subjec ts are or are not c onsuming gluten. IL-15 induc es an intense immunologic al response in CD, with the produc tion of nitrites and IFN gamma [37] .
SEROLOGY
Serological markers of significance include EMA and tTG antibodies. The sensitivity of tTG is 98% and specificity 96%, whereas the EMA is 100% specific and sensitivity is greater than 90% [38] . Assays for tTG antibodies are largely based on the dominant antigen in the EMA test, however, tTG assays are more reliable and more reproduc ible, largely because the EMA is a qualitative assay and tTG assays are quantitative.
The antibodies to tTG and deamidated gliadin peptide (DGP) have been c ombined in a multiplex immunoassay of persons suspec ted as having CD, to potentially provide a c omplete antibody phenotype [39] , and thereby to improve the performanc e c harac teristic s of the serologic al testing. A meta-analysis has shown that the tTG antibody test out-performs the DGP antibody test, with a 5.2% greater sensitivity (93.0% vs 87.8%) and a 2.4% greater specificity (96.5% vs 94.1%), respec tively [40] . DGP has been suggested to possibly be a better diagnostic test for CD before institution of a GFD than is the c onventional gliadin antibody testing: the sensitivity, specificity, and accuracy of deamidated gliadin-IgA (74%, 95%, and 86%), deamidated gliadin-IgA (65%, 98%, and 84%), and deamidated gliadin-IgA + IgG (75%, 94%, and 86%), were superior to gliadin-IgA (63%, 90%, and 79%) (P > 0.05) and gliadin-IgG (42%, 90%, and 60%) (P > 0.01), and were similar to tTG-IgA (78%, 98%, and 90%) [39] . Further c omparative evaluation with more modern serologic al assay methods would be useful, inc luding tTG antibodies.
Bec ause the small bowel biopsy in the person with CD does not have a pathognomic histologic al feature, serologic al testing may have an important supportive role in providing added information for the diagnosis of CD. Tissue transglutaminase (tTG) c atalyzes the Ca 2+ -dependant formation of cross links between protein-bound glutamine and glyc ine residues. The glutamine residue c an be deamidated to glutamic acid by tTG, including specific glutamines in gluten-containing proteins. Deamidated gluten proteins have enhanced affinity for the HLA-DQ heterodimer of antigen-presenting c ells. This ac tivates T-lymphoc ytes and produc es a T-helper type 1 response in the muc osa of c eliac patients. The tTG-gluten c omplex is processed by B-cells, and presented to gluten-specific T c ells, that give rise to tTG antibody T-helper type 2 response [41] . The tTG autoantibodies interac t with extrac ellular membrane-bound transglutaminase, and thereby play an important role in proliferation of epithelial c ells in persons with predisposition to CD.
The tTG is responsible for post-translational modification of proteins by introduction of lysine crosslinks, as well as deamidation. The IgA anti-tTG responses in CD and in dermatitis herpetiformis are foc used on the region of tTG responsible for its transamidation and deamidation reac tions, whereas the IgG response targets other regions of the enzyme [42] .
The performanc e of serum anti-tTG may depend on c linic al presentation of CD; e.g. c lassic symptomatic disease or silent asymptomatic disease. In patients estimated to have Marsh-Ⅲ A, B, or C degree of villous atrophy, the sensitivity, spec ific ity, positive and negative predictive values of the anti-tTG antibody test were 71%, 65%, 91%, and 30%, respec tively [43] . The sensitivity was 90% for subjec ts with total villous atrophy, and only 42% for those with partial villous atrophy. In persons thought to have a high pretest probability of having CD based on symptoms suc h as weight loss, anemia, or diarrhea, 9.1% were antitTG negative [44] , indic ating that serologic al testing may miss a substantial number of c ases of untreated CD that are antibody negative. Strongly positive tTG assay results without CD biopsy c hanges have also been rec orded [45] . In the latter, it is not known if further biopsies at a later date will reveal the typic al morphologic al c hanges of untreated CD.
The supply sources for EMA are limited to monkey esophagus or umbilic al c ord, and many assays are done "inhouse" that may not be readily duplic ated in other laboratories. EMA are considered to be highly sensitive and specific for serologic al c hanges seen in untreated CD. However, EMA assays are expensive, qualitative, and therefore subjec tive. EMA is inc reasingly being replac ed by serologic al testing for antibodies to tTG, espec ially sinc e the anti-tTG assay can be more precisely quantitated.
The EMA binding patterns and serum samples from CD patients are tTG-2 targeted, and the humoral response against tTG oc c urs at the level of the intestinal muc osa. tTG-2 targeted extrac ellular IgA deposits have been demonstrated by immunofluorescence in the small bowel muc osa in untreated c eliac subjec ts, even when they are absent from the serum. In those subjec ts suspec ted of having CD but who are EMA and anti-tTG negative, finding the tTG-2 targeted antibody in the jejunal mucosa may help to make the diagnosis of CD [46] . Frozen sec tions of small bowel spec imens were evaluated by immuno-fluorescence using rabbit antibody against human IgA. Although at best, semi-quantitative, these immunofluorescent deposits may be better initial markers for gluten sensitivity than small bowel muc osal IEL densities [47] . While arc hitec tural c hanges, suc h as villous atrophy, may lead to suspicion of untreated CD, tTG-2 specific IgA deposits may potentially be more useful. Further studies are needed.
Seronegative (EMA or tTG) CD oc c urs in less than 10% of c eliac s, partic ularly in those with lesser degrees of villous atrophy. The presenc e of EMA in subjec ts with an arc hitec turally-normal small bowel biopsy c ould indic ate early developing CD. Serum and intestinal c eliac anti-autobodies and intra-epithelial lymphoc ytes have been assessed as possible indic ators of developing CD. Celiac autoantibody deposits have been rec orded to provide a sensitivity and specificity of 93% and 93%, respectively, in detecting subsequent CD; this is compared to 59% and 57% for CD3+; 76% and 60% for gamma-delta+, and 88% and 71% for villous tip intra-epithelial lymphoc ytes [48] . Simple "in the office" anti-tTG tests have been developed c ommerc ially, and the blood drop-based assay for IgA anti-tTG was reported to have a sensitivity of 90% and a specificity of 95% [49] . The sensitivity and specificity of serum anti-tTG is laboratory-dependent, and assay results may differ for c linic al c ompared to researc h laboratories. Bec ause CD does not have a pathognomic histologic al feature, serology may have a supportive role in making the diagnosis. As CD is defined as a glutensensitive enteropathy, a c linic al or serologic al response to a GFD is essential to establish a diagnosis of CD. Sometimes, re-biopsy after a GFD is nec essary, or even further evaluation after a gluten challenge may be required.
A normal tTG level does not predic t rec overy of villous atrophy in c eliac subjec ts on a GFD. For example, 16 of 48 (33%) subjec ts with CD on a GFD had persistent villous atrophy, but 7 of these 16 (44%) had a normal tTG [50] . In a multic enter, prospec tive study involving adult subjec ts attending one of several primary c are prac tic es, and in individuals not having symptoms or a c ondition known to be associated with CD, initial testing was done with anti-tTG. Those with elevated anti-tTG were tested for EMA (IgA), and then those in turn who were positive for EMA underwent an intestinal biopsy and HLA typing [51] . A positive anti-tTG was found in 3.1%, and the prevalenc e of CD in the serologic ally sc reened sample was 2.3%. When a similar study was performed in a university hospital, the prevalenc e of CD was 3.5%, and a negative HLA-DQ type exc luded the diagnosis [52] . However, the "addition of HLA-DQ typing to TGA and EMA testing, and the addition of serologic al testing to HLA-DQ typing, provided the same measures of test performanc e as either testing strategy alone" [52] . Bec ause the EMA and anti-tTG responses may remain elevated in CD on a GFD, it may be useful to measure soluble CD163, a sc avenger rec eptor shed by tissue macrophages and correlated with the inflammatory lesion in CD. Those subjec ts with a more severe (Marsh grade 3) lesion had higher levels of CD163 than did those with a milder (Marsh grade 2, grade 1 or grade 0) lesion [53] . Further studies are needed.
There are three fatty ac id binding proteins in the c ytosol of the intestine: intestinal FABP (I-FABP), liver FABP (L-FABP), and ileal bile ac id binding protein (I-BABP). These are present in inc reased amounts in the serum of persons with enteroc yte damage from, for example, mesenteric thrombosis or nec rotizing enteritis. Bec ause I-FABP and L-FABP are found predominantly in the enteroc ytes in the upper portion of the jejunal villi, it is not surprising that their c onc entration is inc reased in the plasma of persons with CD. When measurements were made within one year of the introduc tion of a GFD, these initially inc reased Iand L-FABP levels fell to normal [54] . Together with following the patient's symptoms, quality of life, and celiac serology, assessing intestinal permeability may potentially prove to be a useful non-invasive test to follow the histologic al improvement of CD patients on a GFD.
The c urrent standard for the assessment of adherenc e to a GFD in adult CD patients is largely based on a personal c linic al evaluation. However, most serologic al assays appear to compare adequately in sensitivity and specificity to a thorough nutritional evaluation of the assessment of adherenc e to a GFD [55] . This is important, sinc e only approximately 45%-80% of patients with CD adhere stric tly to a GFD. This is thought to place them at increased risk of developing metabolic bone disease, anemia, gastrointestinal symptoms, as well as impaired psyc hologic al wellbeing and quality of life.
MUCOSAL HISTOLOGY
Criteria for the diagnosis of CD inc lude the initial demonstration of small bowel arc hitec tural c hanges inc luding muc osal villous atrophy with c rypt hyperplasia, along with inc reased intra-epithelial lymphoc ytosis. However, this may be a slowly developing proc ess and the c hanges are not spec ific . In addition, some persons may suffer from CD symptoms before histologic al evidenc e c an be doc umented. While some authors have suggested that an anti-tTG level can be defined which gives a positive predic tive value of 100% for CD [56] , it remains the standard of prac tic e to always obtain a biopsy to determine if the histologic al c hanges of untreated CD are present before initiation of a GFD.
Some have noted that there may be significant differenc es between pathologists in muc osal biopsy interpretation [57] . The older Marsh classification, as modified by Oberhuber and c olleagues, c ontinues to be used by many pathologists. But for some, it may be c onsidered c omplex bec ause there are many different diagnostic c ategories. A simpler grading system has been proposed [57] based on three villous morphologies (A, non-atrophic ; B1, atrophic , villous-ratio < 3:1; B2, atrophic , villi no longer detectable), and an intraepithelial lymphocyte c ount of > 25/100 enteroc ytes. Compared to the older classification system, this simpler classification schema was thought by the investigators to be superior.
However, the severity of villous atrophy based on histological analysis of biopsy specimens taken from the proximal intestine does not nec essarily predic t the severity of symptoms in CD for either c hildren or adults. For example, when c linic al symptoms of 18 CD patients with a good histologic al rec overy were c ompared with 13 CD who had persistent small intestinal villous atrophy despite maintaining a GFD, symptoms c ould be absent despite the persistenc e of morphologic al abnormalities [58] . Other authors also noted the lack of association between the histologic al CD lesion and c linic al manifestations [59] . Indeed, the lack of correlation between the degree of villous atrophy and symptoms was stressed in a further study of 499 CD patients, in whic h 44% had a c lassic al presentation and 56% had atypic al or silent CD [60] . These findings are not surprising, however, sinc e the response to a GFD oc c urs initially in the most distal small bowel. Months to even years on a stric t GFD may be needed before improvements in the proximal intestinal muc osa oc c ur.
While duodenal biopsy represents the "gold standard" for the diagnosis of CD, c apsule endosc opy (CE) has revealed that over a third of c eliac patients have mac rosc opic muc osal c hanges extending beyond the duodenum, and in approximately 7%, the entire small bowel was involved [61] . As c ompared with duodenal biopsy for detec ting c hanges in CD, the sensitivity of CE was reported to be 88%, spec ific ity 91%, positive predic tive value 97%, and negative predic tive value 71%.
"Latent CD" is defined as abnormal c eliac serology and a normal small bowel biopsy (Marsh stage 0). These so-c alled "latent CD" patients have an inc reased hazard (HR) ratio for death c omparable to those with Marsh 1-2 and Marsh 3: 1.35; 95% CI, 1.14-1.58, median follow-up, 6.7 years; HR, 1.72; 95% CI, 1.64-1.79; median follow-up, 7.2 years; HR, 1.39; 95% CI, 1.33-1.45; median follow-up, 8.8 years, respec tively [62] . This c orresponded with exc ess mortality of 1.7 per 1000 person-years in "latent CD", 10.8 in Marsh 1-2, and 2.9 in Marsh 3 stage CD. This raises the possibility that it may be important to diagnose very early CD. However, this label of "latent CD" may differ from the original definition of latent CD (without serologic al studies) where abnormal small intestinal arc hitec tural c hanges were induc ed with a high gluten-c ontaining diet (initially reported in dermatitis herpetiformis) and then normalized on a GFD.
Given that duodenal biopsy is still the "gold standard" for the diagnosis of CD, it is of interest to know that when only two duodenal biopsies are obtained, diagnosis of untreated CD is confirmed in 90%, however, inc reasing the number of biopsies to 3 inc reased detection to 95%, and to 4 biopsies, 100% respec tively [63] . While some present with symptoms and a small bowel biopsy is done to exc lude CD, others will present with positive serology and a duodenal biopsy is then obtained. Oc c asionally lesions may be patc hy or detec ted only in the duodenum, resulting in potential for sampling error and a false-negative result. Confoc al endomic rosc opy (CEM) is a novel method that permits magnific ation in vivo of the gastrointestinal muc osa by up to 1000-fold. In persons with known CD, accuracy of CEM in diagnosing CD was reported to be exc ellent, with rec eiver operator c harac teristic s under the curve of 0.946, sensitivity of 94%, and specificity of 92% [64] . CEM was also sensitive in the detec tion of histologic al c hanges following treatment with a GFD.
"Lymphoc ytic enteritis" (Marsh 1) may be assoc iated with symptoms, yet serological markers of CD appeared to be of limited value in identifying these individuals. In 130 of 221 first-degree relatives of HLA-DQ2-positive patients with CD, relatives were positive also for HLA-DQ2, and 49% were Marsh 0, 25% Marsh 1, < 1% Marsh 2 and 10% Marsh 3. Only 17 of 221 relatives had positive serological markers for CD [65] . These authors argued that the higher number of symptomatic patients with lymphoc ytic enteritis (Marsh 1) supports HLA-DQ2 genotyping strategy followed by duodenal biopsy in relatives of CD patients. Further studies to confirm these observations are needed.
Anti-tTG levels have c ontinued to be used in assessing initiation and maintenanc e of a GFD. It is believed that tTG levels might be followed to reduce the risk of c omplic ations and monitor histologic al c hanges in the upper small bowel [66] .
CLINICAL PHENOTYPES
The ESPGHAN (European Soc iety of Pediatric Gastro-enterology, Hepatology and Nutrition) c riteria distinguish between three different forms of CD so that classification might be more prec ise: the latent or potential form defined by the presenc e of anti-c eliac antibodies; the silent form (asymptomatic) defined by the presence of anti-celiac antibodies and villous atrophy of the small intestine; and the symptomatic form defined by the presence of anti-celiac antibodies, villous atrophy and c linic al symptoms.
The adult height of c hildren with c lassic al CD (e.g. symptomatic with diarrhea) is influenced by their complianc e to a GFD. Children diagnosed with CD after 4 years of age show a slower and less c omplete c atc h-up growth. A delayed diagnosis of CD may be assoc iated with a shorter adult height in men, but not in women [67] . While abdominal symptoms may respond quickly to a GFD, it may take up to a year or more after the introduction of a GFD for persons with CD to ac hieve normalization of their initially abnormal small bowel biopsy. Elderly patients respond more slowly than younger patients to a GFD.
"Gluten sensitivity" may be defined as symptoms, suc h as diarrhea, apparently induc ed by gluten-c ontaining foods. These have been reported in the absenc e of c hanges in small intestinal histology. In persons with diarrheapredominant irritable bowel syndrome (D-IBS), stool frequency and the gastrointestinal symptoms score return to normal values in 60% of D-IBS subjec ts who were positive for HLA-DQ2 and CD-assoc iated serum IgG after six months on a GFD, c ompared to only 12% who were negative [68] . Among the c omplic ations of undiagnosed and, therefore, untreated CD are growth failure in c hildren, infertility, anemia, osteoporosis, small intestinal non-Hodgkin lymphoma [69] , and a 3.9-fold inc reased all-c ause mortality rate [70] . Potentially, this may undersc ore the importanc e of diagnosing and treating even latent CD.
Celiac patients were reported to have a 5.4-fold higher risk of non-Hodgkin's lymphoma, but no increased risk of Hodgkin's or chronic lymphatic leukemia. A shared susc eptibility amongst siblings is observed [69] . It remains c ontroversial whether there is an increased risk of developing lymphoma in CD if the disease is asymptomatic [58, 71] . There is a 5-fold increase in risk of lymphoproliferative malignanc y in CD in c omparison to the general population [72] .
CLINICAL ASSOCIATIONS
The prevalenc e of autoimmune diseases (e.g. autoimmune thyroid disease) is inc reased in persons with CD, as c ompared with the healthy c ontrol population. Conversely, CD is inc reased in persons with autoimmune diseases. The cumulative risk of autoimmune disease in patients with CD is 8% at age 15, and 16% at age 30 years. Fac tors associated with an increased risk of autoimmune diseases assoc iated with CD inc lude a family history of autoimmune disorders, and a diagnosis of CD before the age of 36 [73] . Onc e the diagnosis of CD has been made, patients who are adherent to a GFD have a 6% risk of developing autoimmune disease at 10 years, vs 16% in those who are not c ompliant with a GFD. Expressed differently, the inc idenc e of autoimmune disease is 5.4 per thousand patient years during adherenc e to a GFD, vs 11.3 per thousand patient years during non-adherenc e.
Asymptomatic CD is also seen in c hildren and adults with autoimmune hepatitis and autoimmune bile duc t disease. CD may be assoc iated with asymptomatic inc reases in transaminase values. Persons with autoimmune liver disease should be examined for possible CD. In persons with CD who have ac ute hepatitis, an autoimmune c ause should be suspec ted [74] . More and more c linic al assoc iations have been suggested for CD. For example, 42% of CD patients had oral soft tissue lesions, as c ompared to only 2% of non-CD patients [75] . Rec urrent aphthous stomatitis disappeared in 89% of patients after one year of a GFD.
Biopsy-defined CD has a 4-fold higher prevalence in those with irritable bowel syndrome [76] . Mental disorders, non-c omplianc e with the GFD, ac tive medic al c o-morbidities, and dissatisfac tion with doc tor/patient c ommunic ation were assoc iated with reduc ed CD Questionnaire sc ores [77] . Up to 10% of patients with CD have neurologic al symptoms ranging from polyneuropathy, epilepsy, myoclonus, multifocal leukoencephalopathy, dementia, chorea, migraine, memory/attention impairment and peripheral axonal and demyelinating neuropathies as well as ac etylc holine-antibody positive myasthenia gravis [78] . Autoimmunity may ac t as a mec hanism triggering neurologic al dysfunc tion [79] , and anti-neuronal, anti-gliadin and tTG antibodies may c ontribute to neurologic al impairment through Apaf-1 ac tivation with Bax and c ytoc hrome C transloc ation, leading to impairment of mitoc hondrialdependent apoptosis. There is no statistically significant association between CD and subsequent development of Parkinson's disease, Alzheimer's disease, hereditary ataxia, symptoms of ataxia, Huntington's disease, or spinal musc ular atrophy [80] . Adult but not pediatric patients with CD have an increased risk of sepsis, particularly pneumococcus infection [81] . In CD there is an inc reased prevalenc e of splenic hypofunc tion [82] . Using community-based cohorts and a record-linkage database, the adjusted relative risk of cardiovascular disease in CD was 2.5 for new EMA positive vs EMA negative individuals [83] . This suggests that CD may be assoc iated with an increased risk of cardiovascular outcome. There may also be an assoc iation between CD and eosinophilic esophagitis [84] . Aldolase B deficiency causes hereditary fructose intoleranc e, and this may be assoc iated with CD [85] . In CD patients as compared with individuals with dyspepsia or healthy controls, serum ghrelin concentrations are higher, not c orrelated to the severity of duodenal histologic al lesions, and revert to normal during the institution of a GFD, despite persistent duodenal lymphoc ytic infiltration [86] . It is not c lear if these alterations in ghrelin c onc entrations have any biologic al importanc e in CD.
In 18 CD patients, there was increased intestinal 5-HT-enterochromaffin cell numbers, higher peak plasma 5-HT levels and postprandial area under the c urve of 5-HT levels after a high-c arbohydrate meal, as well as inc reased platelet 5-HT stores [87] . The authors suggested that serotonin exc ess may mediate dyspeptic symptoms in untreated CD. Further evaluation is required.
A meta-analysis of serologic al or histologic al diagnosis of CD in unselec ted adults with dyspepsia showed that the numeric ally inc reased prevalenc e was not statistic ally significant [88] . Another systematic review and meta-analysis by the same group, examining 14 studies with 2,278 persons diagnosed with IBS, had an approximately 4% prevalenc e of CD. The OR for biopsy-proven CD in IBS c ases vs c ontrols was 4.34 [89] . In c hildren with CD, 40% had elevated transaminase values; of those with elevated transaminase values, 95% were c ryptogenic and normalized on a GFD, and 5% had autoimmune hepatitis that required immunosuppression plus a GFD to normalize c linic al and bioc hemic al parameters [90] .
TREATMENT

Gluten free diet
What is the definition of a GFD? Even "gluten-free" produc ts may not be c ompletely free of gluten. In 1998, the World Health Organization/Food and Agric ulture Organizations Commission proposed that foods whic h are said to be "gluten-free" c ould not c ontain more than 200 ppm of gluten. Eac h individual with CD may have a unique threshold or tolerance to the amount of gluten in the diet. Daily gluten intake of less than 10 mg is unlikely to cause significant histological abnormalities in the intestine of patients with CD [91] . Patients adhering to a GFD report an improved health related quality of life.
A systematic review has revisited the c omplic ations and need for long term follow-up in CD [92] . A 16-question disease-specific symptom index has been validated in adults with CD [93] . Suc h an index might be used to monitor the response of a CD patient to a GFD.
The treatment of CD is the life-long use of a GFD. A primary goal in the c are of patients with CD is to improve the quality of their lives, through a collaboration of the stakeholders [94] . Lanzini et al [95] assessed in 465 c onsec utive CD patients, the histologic al outc ome after a GFD c onsumed for a median of 16 mo. While CD serology bec ame negative in 83% of CD patients with Marsh Ⅲ lesions on a GFD, muc osal biopsy histology normalized in only 8%, improved exc ept for inc reased intraepithelial lymphoc ytes in 65%, was unc hanged in 26% and worsened in 1%. The authors c onc luded that "c omplete normalization of duodenal lesions is exc eptionally rare in adult c eliac patients despite adherenc e to GFD, symptoms disappearanc e and negative CD related serology".
Early diagnosis and treatment are important in CD, as some of the assoc iated c omplic ations may be irreversible, unless the CD is treated [96] . Growth retardation, osteoporosis and abnormal dentition will remain permanent if not treated early. The prevalenc e of assoc iated depression is up to 37%, similar to that of persons with other c hronic c onditions [97] . In c hildren with CD, long-term c onsumption of oats may be well tolerated [98] , although c onc ern has been expressed regarding possible c ontamination of oats with other gluten-c ontaining grains. Other investigators have demonstrated that transamidation of wheat flour inhibits the response to gliadin of intestinal T c ells in CD [99] . It has always been assumed that patients with CD must remain on a GFD for life. However, up to 10% of CD patients diagnosed in c hildhood were reported to develop long-term latenc y of their CD when returning to a gluten-c ontaining diet [100] . In patients who have been on a GFD and have no symptoms, even if there were small bowel CD-like histological abnormalities which remained, some had no evidenc e of c linic al relapse even though they had been on a gluten-c ontaining "normal" diet for more than 2 years.
Individuals with villous atrophy but no symptoms are said to have "silent" CD. Almost half of CD patients may clinically tolerate a gluten-containing diet, yet c ontinue to have muc osal abnormalities. Indeed, approximately 10% of CD patients diagnosed in c hildhood may develop c linic al toleranc e to gluten. In the United Kingdom, about one-third of CD subjec ts are under no ac tive follow-up [101] .
Alternatives to a gluten free diet
There may be poor c omplianc e with the GFD bec ause it is difficult and gluten-free products are expensive. For these reasons, new approaches have been taken in the treatment of CD. Some of these inc lude orally administered endopeptidase, antagonists to S100B protein, IL-15 blockers, elemental diets and transamidation of wheat flour. Lactobacilli added to sourdough for fermentation are able to break down the proline-/glutamine-rich gluten peptide. This may play a role in the future treatment of CD [102] . Supplementation of nutrients may bec ome essential depending upon the severity of malnutrition. One double-blind plac ebo-c ontrolled multic enter trial showed a significant improvement in general well being after 6 mo of supplementation with vitamin B [103] . Prolyl-endopeptidases are able to digest ingested gluten. Oral therapy with prolyl-endopeptidases, exogenous protease enzymes, represents a new approac h to managing CD [104] . Bac terial prolyl-endopeptidase from Flavobacterium meningosepticum removes gluten toxic ity by cleaving it into small fragments which lack T-cell stimulatory properties [105] . After prolonged exposure to high concentrations of bacterial prolyl-endopeptidase, the amount of immunostimulatory gliadin peptides reac hing the loc al immune system in CD is dec reased [106] . The prolyl-endoprotease from Aspergillus niger (AN-PEP) is a member of the serine peptidase family, and this degrades gluten peptides rapidly [107] . This AN-PEP is c apable of ac c elerating the degradation of gluten in a gastrointestinal model that c losely mimic s in-vivo digestion [108] . The pH optimum of the enzyme is compatible with that found in the stomac h, and the enzyme is resistant to degradation by pepsin.
The gluten proteins may be purposely modified to abolish their c apac ity to stimulate the interferon gamma from CD4+ T-c ells [109] . Another approac h to the therapy of CD is the designing of non-toxic wheat, rye or barley based on their protein homology [110, 111] . Other therapeutic approac hes would include the binding of gluten to HLA-DQ2 or HLA-DQ8, or blocking the gluten-reac tive T c ells by immunotherapy (e.g. vaccination). For example, transamidation of wheat flour with a food-grade enzyme and an appropriate amine donor (mic robial transglutaminase and lysine methyl ester) can be used to block the T-cell mediated gliadin activity [99] . Gluten c ontains many immunogenic peptides, but there may be weak varieties with a natural low number of T-c ell-stimulatory epitopes [111] . Polymeric binders reduc e the deleterious effec ts of gliadin on intestinal epithelium in c ultured c ells and transgenic mic e [112] . These binders have a strong affinity for gliadin, inhibiting cytoskeleton disorganization and ultrastruc tural c hanges in intestinal epithelial c ells. Their beneficial use in humans remains to be established.
Antigen-presenting c ells inc lude dendritic c ells, macrophages and B-cells. A unique subset of dendritic cells appears to be responsible for loc al ac tivation of glutenreac tive T-c ells in the c eliac lesion [113] . Enteric glial c ells (EGC) release neurotropic fac tors and are ac tivated by inflammatory insults. EGC-derived S100B protein released in astroglial c ells is inc reased in the duodenum of patients with CD, with inc reased S100B messenger RNA and protein expression, inc reased iNOS protein expression, and inc reased nitrite produc tion in treated CD [114] . This does not oc c ur in those CD patients on a GFD, or in non-CD control subjects. Products derived to block EGC-derived S100B protein may have a therapeutic role.
IL-15 has proinflammatory and anti-apoptotic properties. IL-15 is over-expressed in the enteroc ytes and lamina propria mononuc lear c ells of untreated CD, where its level reportedly c orrelates with the degree of muc osal damage [115] . IL-15 also promotes IEL survival. Blocking IL-15 and suppressing unc ontrolled IEL ac tivation and survival has the potential to provide a new therapeutic approac h to prevent tissue damage in CD. In the intestinal muc osa of CD patients, IL-15 impairs Smad3-dependant TGFbeta signaling in human T-lymphoc ytes downstream from Smad3 nuc lear transloc ation [116] . There is upregulation of phosphor-c -jun. This provides further support to the suggestion of the potential therapeutic effect of blocking IL-15.
Intestinal permeability is inc reased in patients with CD, and is assoc iated with alterations in tight junc tion proteins (e.g. zonulin). Addition of zonulin may prevent T-c ell mediated stimulation in CD. In a double-blind randomized plac ebo-c ontrolled study of milligram doses of AT-1001, an inhibitor of parac ellular permeability derived from Vibrio cholera, prevented the expec ted inc reases in intestinal permeability in subjec ts with CD c hallenged with gluten [117] . AT-1001 use is also assoc iated with a diminution in the antic ipated rise of interferon-gamma levels.
REFRACTORY DISEASE
Rec urrent symptoms sometimes develop in biopsy-proven CD patients on a GFD. The most c ommon c ause of nonresponsive CD, whic h oc c urs in about 30% of CD patients, is non-adherenc e to a GFD. A Celiac Dietary Adherenc e Test (CDAT) consistency in a 7-item questionnaire was developed using a logistic regression, and validated against transglulaminase serology for the assessment of adherenc e to a GFD [118] . Usually, poor c omplianc e to a GFD is thought to be responsible, although c omplianc e may sometimes be difficult to establish. Intentional dietary indiscretion may be evident, but sometimes, there is limited awareness of gluten-containing substances. Gluten is ubiquitous, being doc umented in pill c apsules and other materials, suc h as c ommunion wafers.
Other c auses, detailed elsewhere [119] , may be responsible for rec urrent symptoms even though the CD patient appears to be following a stric t GFD. Some c auses inc lude associated primary or secondary pancreatic insufficiency, small intestinal bac terial overgrowth, c ollagenous sprue, or lymphoc ytic or c ollagenous c olitis. Rarely, a c omplic ation may be responsible (e.g. lymphoma, c arc inoma).
Sometimes, no initial response to a GFD ever oc c urs and symptoms persist. In these subjec ts, biopsies may be abnormal, but the gluten-dependent nature of the small bowel abnormalities was never doc umented. This has been labeled "unclassified sprue" or "sprue-like intestinal disease". Some of these persons may eventually prove to have a lymphoma. As many as approximately half of patients with CD on a GFD for more than two years may be able to tolerate a gluten c hallenge, even though they have muc osal abnormalities [100] . About 10% of CD patients diagnosed in c hildhood may develop temporary toleranc e to gluten. However, bec ause of the c ontinuing mucosal abnormalities, they remain at risk of developing the c omplic ations of CD. Indeed, adolesc ents who do not adhere to a GFD have a lower quality of life [120] . Immunohistochemical labeling has helped to define an abnormal prognostic profile of intra-epithelial lymphoc ytes in the small bowel muc osa, so-c alled "refrac tory c eliac disease, type 2 (RCD 2)" c harac terized by an aberrant c lonal IEL population with loss of IEL antigens. About half of RCD 2 patients develop an enteropathyassoc iated T-c ell lymphoma (EATL) within 5 years, and a partic ular HLA-DQ subtype, DQ2, if homozygous, predisposes to RCD 2 [121] . Complete duodenal muc osal rec overy in CD may be limited and may require prolonged periods of a GFD. In one study, remission was seen in 65% or no histologic al improvement was seen in 26% of patients [95] . This might be antic ipated, however, if only duodenal biopsies are being taken since the proximal small intestine is most severely affected and varying periods of time are required for recovery to be significant. An apparent failure to histologically respond to a GFD may only reflect that duo-denal, rather than more distal small intestinal biopsies were repeated.
Refractory CD has been defined as persistent or recurrent villous atrophy with c rypt hyperplasia and inc reased intraepithelial lymphoc ytes (IELs) despite a stric t GFD for greater than 12 mo (or if severe persisting symptoms nec essitate intervention independent of the duration of the GFD) [122] . In assessing the GFD response, the site of rebiopsy and duration on a stric t GFD are c ruc ial to the definition of refrac tory disease. In some, as suggested by this definition, the opportunity for re-evaluation is very limited bec ause of rapid progression of the intestinal disease.
RCD is usually manifested by rec urrenc e of symptoms and intestinal abnormalities, despite adherenc e to a GFD. RCD can be further defined from a prognostic perspec tive by the histologic al appearanc e of monoc lonal or polyc lonal intraepithelial lymphoc ytes (RCD type 2) vs normal lymphoc ytes (type 1) [123] . These c hanges and the development of an EATL were shown to be adverse factors in the prognosis of CD, particularly in the first two years after CD has been deemed to be refrac tory [124] . Refrac tory c eliac disease (RCD) type 2 but not type 1 shortens the sufferer's life expec tanc y [123] . Cortic osteroids may improve c linic al symptoms in some patients with RCD. Unfortunately, the histological response to steroids has not been consistent [123] . Patients with RCD 1 may benefit from immunosuppressive therapy, whereas those with RCD 2 may respond to Cladribine or to stem c ell transplantation. Treatment with c ladribine and anti-CD-52 has been shown to be assoc iated with histologic al improvement. Azathioprine and anti-tumor nec rosis fac tor-α have shown only limited suc c ess. The development of an overt lymphoma within 8 wk of treatment was seen in 3 out of 4 of these patients, thereby preventing further use. Alternative strategies that have been suggested inc lude stem c ell transplantation to replac e the abnormal intra-epithelial lymphocyte population, and the blocking of IL-15 [125] [126] [127] [128] [129] .
CONCLUSION
Celiac disease is being inc reasingly diagnosed bec ause of the rec ognition that the disease may be present without signific ant intestinal symptoms, may be assoc iated with other autoimmune disorders and may be suspec ted from serological screening. Definition of the disease includes an intestinal biopsy before treatment with a GFD along with doc umentation of a definitive GFD response. In some patients, this may nec essitate further intestinal biopsy after a period on a GFD. Serologic al testing may be useful in providing additional evidenc e that CD is present and may be useful in some patients to assess GFD c omplianc e. Rec ent studies foc used on the genetic basis and pathogenesis of CD have emerged to improve understanding of the c omplex molec ular alterations that oc c ur with CD.
